Cargando…
Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment
Although statins are widely prescribed medications, there remains considerable variability in therapeutic response. Genetics can explain only part of this variability. Metabolomics is a global biochemical approach that provides powerful tools for mapping pathways implicated in disease and in respons...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192752/ https://www.ncbi.nlm.nih.gov/pubmed/22022402 http://dx.doi.org/10.1371/journal.pone.0025482 |
_version_ | 1782213787641708544 |
---|---|
author | Kaddurah-Daouk, Rima Baillie, Rebecca A. Zhu, Hongjie Zeng, Zhao-Bang Wiest, Michelle M. Nguyen, Uyen Thao Wojnoonski, Katie Watkins, Steven M. Trupp, Miles Krauss, Ronald M. |
author_facet | Kaddurah-Daouk, Rima Baillie, Rebecca A. Zhu, Hongjie Zeng, Zhao-Bang Wiest, Michelle M. Nguyen, Uyen Thao Wojnoonski, Katie Watkins, Steven M. Trupp, Miles Krauss, Ronald M. |
author_sort | Kaddurah-Daouk, Rima |
collection | PubMed |
description | Although statins are widely prescribed medications, there remains considerable variability in therapeutic response. Genetics can explain only part of this variability. Metabolomics is a global biochemical approach that provides powerful tools for mapping pathways implicated in disease and in response to treatment. Metabolomics captures net interactions between genome, microbiome and the environment. In this study, we used a targeted GC-MS metabolomics platform to measure a panel of metabolites within cholesterol synthesis, dietary sterol absorption, and bile acid formation to determine metabolite signatures that may predict variation in statin LDL-C lowering efficacy. Measurements were performed in two subsets of the total study population in the Cholesterol and Pharmacogenetics (CAP) study: Full Range of Response (FR), and Good and Poor Responders (GPR) were 100 individuals randomly selected from across the entire range of LDL-C responses in CAP. GPR were 48 individuals, 24 each from the top and bottom 10% of the LDL-C response distribution matched for body mass index, race, and gender. We identified three secondary, bacterial-derived bile acids that contribute to predicting the magnitude of statin-induced LDL-C lowering in good responders. Bile acids and statins share transporters in the liver and intestine; we observed that increased plasma concentration of simvastatin positively correlates with higher levels of several secondary bile acids. Genetic analysis of these subjects identified associations between levels of seven bile acids and a single nucleotide polymorphism (SNP), rs4149056, in the gene encoding the organic anion transporter SLCO1B1. These findings, along with recently published results that the gut microbiome plays an important role in cardiovascular disease, indicate that interactions between genome, gut microbiome and environmental influences should be considered in the study and management of cardiovascular disease. Metabolic profiles could provide valuable information about treatment outcomes and could contribute to a more personalized approach to therapy. |
format | Online Article Text |
id | pubmed-3192752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-31927522011-10-21 Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment Kaddurah-Daouk, Rima Baillie, Rebecca A. Zhu, Hongjie Zeng, Zhao-Bang Wiest, Michelle M. Nguyen, Uyen Thao Wojnoonski, Katie Watkins, Steven M. Trupp, Miles Krauss, Ronald M. PLoS One Research Article Although statins are widely prescribed medications, there remains considerable variability in therapeutic response. Genetics can explain only part of this variability. Metabolomics is a global biochemical approach that provides powerful tools for mapping pathways implicated in disease and in response to treatment. Metabolomics captures net interactions between genome, microbiome and the environment. In this study, we used a targeted GC-MS metabolomics platform to measure a panel of metabolites within cholesterol synthesis, dietary sterol absorption, and bile acid formation to determine metabolite signatures that may predict variation in statin LDL-C lowering efficacy. Measurements were performed in two subsets of the total study population in the Cholesterol and Pharmacogenetics (CAP) study: Full Range of Response (FR), and Good and Poor Responders (GPR) were 100 individuals randomly selected from across the entire range of LDL-C responses in CAP. GPR were 48 individuals, 24 each from the top and bottom 10% of the LDL-C response distribution matched for body mass index, race, and gender. We identified three secondary, bacterial-derived bile acids that contribute to predicting the magnitude of statin-induced LDL-C lowering in good responders. Bile acids and statins share transporters in the liver and intestine; we observed that increased plasma concentration of simvastatin positively correlates with higher levels of several secondary bile acids. Genetic analysis of these subjects identified associations between levels of seven bile acids and a single nucleotide polymorphism (SNP), rs4149056, in the gene encoding the organic anion transporter SLCO1B1. These findings, along with recently published results that the gut microbiome plays an important role in cardiovascular disease, indicate that interactions between genome, gut microbiome and environmental influences should be considered in the study and management of cardiovascular disease. Metabolic profiles could provide valuable information about treatment outcomes and could contribute to a more personalized approach to therapy. Public Library of Science 2011-10-13 /pmc/articles/PMC3192752/ /pubmed/22022402 http://dx.doi.org/10.1371/journal.pone.0025482 Text en Kaddurah-Daouk et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Kaddurah-Daouk, Rima Baillie, Rebecca A. Zhu, Hongjie Zeng, Zhao-Bang Wiest, Michelle M. Nguyen, Uyen Thao Wojnoonski, Katie Watkins, Steven M. Trupp, Miles Krauss, Ronald M. Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment |
title | Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment |
title_full | Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment |
title_fullStr | Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment |
title_full_unstemmed | Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment |
title_short | Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment |
title_sort | enteric microbiome metabolites correlate with response to simvastatin treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192752/ https://www.ncbi.nlm.nih.gov/pubmed/22022402 http://dx.doi.org/10.1371/journal.pone.0025482 |
work_keys_str_mv | AT kaddurahdaoukrima entericmicrobiomemetabolitescorrelatewithresponsetosimvastatintreatment AT baillierebeccaa entericmicrobiomemetabolitescorrelatewithresponsetosimvastatintreatment AT zhuhongjie entericmicrobiomemetabolitescorrelatewithresponsetosimvastatintreatment AT zengzhaobang entericmicrobiomemetabolitescorrelatewithresponsetosimvastatintreatment AT wiestmichellem entericmicrobiomemetabolitescorrelatewithresponsetosimvastatintreatment AT nguyenuyenthao entericmicrobiomemetabolitescorrelatewithresponsetosimvastatintreatment AT wojnoonskikatie entericmicrobiomemetabolitescorrelatewithresponsetosimvastatintreatment AT watkinsstevenm entericmicrobiomemetabolitescorrelatewithresponsetosimvastatintreatment AT truppmiles entericmicrobiomemetabolitescorrelatewithresponsetosimvastatintreatment AT kraussronaldm entericmicrobiomemetabolitescorrelatewithresponsetosimvastatintreatment |